Jun 2026 (Q2 FY26) — Aug 6, 2026
The Pennant Group Q2 FY26 — Strong Organic Growth and Raised Full-Year Guidance
Read the full callPennant Group (PNTG) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Pennant Group earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 298 | +35.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 5.8 | +0.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 9.1 | +28.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$42.27 +3.55% · +$1.45
Performance +75.6% 1Y
1Y: $24.07 on 14 Oct 2025 → $42.27. High $42.48 (16 Sept 2026), low $23.64 (17 Oct 2025).
- Previous close
- $40.82
- 52-week range
- $23.64 – $42.48
- One year
- +74.38%
Overview
- Symbol
- PNTG
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Pennant Group earnings calls (PNTG)
Financials
What the filings say
Net profit, year on year: +28% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 181 | 189 | 210 | 220 | 229 | 289 | 285 | 298 |
| Expenses | 170 | 180 | 197 | 208 | 219 | 272 | 268 | 281 |
| Operating profit | 11 | 9 | 13 | 12 | 10 | 17 | 17 | 17 |
| Operating margin | 6.0% | 4.9% | 6.0% | 5.3% | 4.5% | 6.0% | 6.1% | 5.8% |
| Interest | 3 | 1 | 1 | 1 | 1 | 3 | 3 | 3 |
| Profit before tax | 8 | 9 | 11 | 11 | 9 | 14 | 14 | 15 |
| Tax rate | 16.9% | 24.1% | 25.1% | 24.6% | 26.8% | 27.3% | 26.9% | 26.5% |
| Net profit | 6 | 6 | 8 | 7 | 6 | 9 | 9 | 9 |
| EPS ($ per share) | 0.20 | — | 0.23 | 0.21 | 0.18 | — | 0.25 | 0.26 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 0 | -4 | 12 | 15 | 21 | 35 | 57 | 87 |
| Total liabilities | 33 | 377 | 406 | 416 | 386 | 394 | 368 | 594 |
| Fixed assets | 10 | 15 | 18 | 17 | 27 | 29 | 43 | 61 |
| Total assets | 98 | 448 | 507 | 530 | 512 | 540 | 680 | 968 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 23 | 10 | 50 | -18 | 9 | 33 | 39 | 48 |
| Cash from investing | -9 | -26 | -42 | -20 | -24 | -30 | -71 | -228 |
| Cash from financing | -14 | 17 | -9 | 43 | 12 | 1 | 50 | 172 |
| Net cash flow | 0 | 0 | -0 | 5 | -3 | 4 | 18 | -7 |
| Capital expenditure | -4 | -7 | -7 | -6 | -14 | -8 | -9 | -12 |
| Free cash flow | 20 | 3 | 43 | -25 | -5 | 25 | 30 | 36 |
Insider filings
39 filings between Nov 11, 2025 and Aug 6, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$690.1K
9 sales by 3 insiders
78% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 25
- Award — granted as compensation
- 5
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Guerisoli Brent | — | $582.7K | Aug 6, 2026 |
| Steik Jason Paul | — | $53.7K | Aug 6, 2026 |
| Cheney Kirk Sterling | — | $53.7K | Aug 6, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 6, 2026 | Steik Jason Paul Chief Clinical Officer | Sale 10b5-1 plan | 1,394 | $53.7K |
| Aug 6, 2026 | Guerisoli Brent Chief Executive Officer | Sale | 4,285 | $165.1K |
| Aug 6, 2026 | Cheney Kirk Sterling EVP, GC and Corp Secy | Sale | 1,393 | $53.7K |
| Jul 15, 2026 | Lamb Scott E Director | Award | 2,400 | $0 |
| Jul 15, 2026 | Christensen Christopher R. Director | Award | 1,900 | $0 |
| Jul 15, 2026 | Snapper Suzanne D. Director | Award | 1,900 | $0 |
| Jul 15, 2026 | Morris Gregory K Sr. Director | Award | 1,900 | $0 |
| Jul 15, 2026 | Nackel John G. Director | Award | 1,900 | $0 |
| Jul 15, 2026 | COVEY STEPHEN M R Director | Award | 1,900 | $0 |
| Jul 15, 2026 | SMITH BARRY M Director | Award | 1,900 | $0 |
| Jul 10, 2026 | Guerisoli Brent Chief Executive Officer | Option exercise 10b5-1 plan | 6,248 | $28.4K |
| Jul 10, 2026 | Guerisoli Brent Chief Executive Officer | Sale 10b5-1 plan | 3,159 | $131.3K |
| Jul 7, 2026 | Guerisoli Brent Chief Executive Officer | Option exercise 10b5-1 plan | 6,249 | $28.4K |
| Jul 7, 2026 | Guerisoli Brent Chief Executive Officer | Sale 10b5-1 plan | 3,165 | $128.2K |
| May 22, 2026 | Guerisoli Brent Chief Executive Officer | Sale 10b5-1 plan | 2,254 | $79.1K |
| May 22, 2026 | Guerisoli Brent Chief Executive Officer | Option exercise 10b5-1 plan | 4,463 | $17.1K |
| May 22, 2026 | Guerisoli Brent Chief Executive Officer | Sale 10b5-1 plan | 22 | $767 |
| May 22, 2026 | Guerisoli Brent Chief Executive Officer | Sale 10b5-1 plan | 2,032 | $71.3K |
| May 22, 2026 | Guerisoli Brent Chief Executive Officer | Sale 10b5-1 plan | 200 | $7.0K |
| May 22, 2026 | Guerisoli Brent Chief Executive Officer | Option exercise 10b5-1 plan | 4,463 | $17.1K |
| Apr 15, 2026 | Snapper Suzanne D. Director | Award | 1,900 | $0 |
| Apr 15, 2026 | SMITH BARRY M Director | Award | 1,900 | $0 |
| Apr 15, 2026 | COVEY STEPHEN M R Director | Award | 1,900 | $0 |
| Apr 15, 2026 | Morris Gregory K Sr. Director | Award | 1,900 | $0 |
| Apr 15, 2026 | Lamb Scott E Director | Award | 2,400 | $0 |
| Apr 15, 2026 | Nackel John G. Director | Award | 1,900 | $0 |
| Apr 15, 2026 | Christensen Christopher R. Director | Award | 1,900 | $0 |
| Mar 3, 2026 | Walbom Lynette Chief Financial Officer | Award | 8,025 | $0 |
| Mar 3, 2026 | Cheney Kirk Sterling EVP, GC and Corp Secy | Award | 2,874 | $0 |
| Mar 3, 2026 | Guerisoli Brent Chief Executive Officer | Award | 11,260 | $0 |
| Mar 3, 2026 | Gochnour John J Chief Operating Officer | Award | 11,214 | $0 |
| Jan 15, 2026 | SMITH BARRY M Director | Award | 1,900 | $0 |
| Jan 15, 2026 | Morris Gregory K Sr. Director | Award | 1,900 | $0 |
| Jan 15, 2026 | Nackel John G. Director | Award | 1,900 | $0 |
| Jan 15, 2026 | Christensen Christopher R. Director | Award | 1,900 | $0 |
| Jan 15, 2026 | COVEY STEPHEN M R Director | Award | 1,900 | $0 |
| Jan 15, 2026 | Snapper Suzanne D. Director | Award | 1,900 | $0 |
| Jan 15, 2026 | Lamb Scott E Director | Award | 2,400 | $0 |
| Nov 11, 2025 | Cheney Kirk Sterling EVP, GC and Corp Secy | Option exercise | 3,800 | $57.3K |
| Oct 15, 2025 | Christensen Christopher R. Director | Award | 1,900 | $0 |
| Oct 15, 2025 | COVEY STEPHEN M R Director | Award | 1,900 | $0 |
| Oct 15, 2025 | Snapper Suzanne D. Director | Award | 1,900 | $0 |
| Oct 15, 2025 | SMITH BARRY M Director | Award | 1,900 | $0 |
| Oct 15, 2025 | Lamb Scott E Director | Award | 2,400 | $0 |
| Oct 15, 2025 | Nackel John G. Director | Award | 1,900 | $0 |
| Oct 15, 2025 | Morris Gregory K Sr. Director | Award | 1,900 | $0 |
| Oct 9, 2025 | SMITH BARRY M Director | Option exercise | 10,000 | $113.5K |
| Jul 28, 2025 | Cheney Kirk Sterling EVP, GC and Corp Secy | Sale | 880 | $20.5K |
| Jul 28, 2025 | Guerisoli Brent Chief Executive Officer | Sale | 3,995 | $93.2K |
| Jul 15, 2025 | SMITH BARRY M Director | Award | 1,900 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Pennant Group, Inc.
Free account. Everything above stays public.
Write why you follow Pennant Group, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading